Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

Objective: To examine the impact on quality of life (QOL) of patients with hATTR amyloidosis with polyneuropathy treated with inotersen (Tegsedi™) versus placebo. Methods: Data were from the NEURO-TTR trial (ClinicalTrials.gov Identifier: NCT01737398), a phase 3, multinational, randomized, double-bl...

ver descrição completa

Detalhes bibliográficos
Autor principal: Coelho, Teresa (author)
Outros Autores: Yarlas, Aaron (author), Waddington-Cruz, Marcia (author), White, Michelle K. (author), Sikora Kessler, Asia (author), Lovley, Andrew (author), Pollock, Michael (author), Guthrie, Spencer (author), Ackermann, Elizabeth J. (author), Hughes, Steven G. (author), Karam, Chafic (author), Khella, Sami (author), Gertz, Morie (author), Merlini, Giampaolo (author), Obici, Laura (author), Schmidt, Hartmut H. (author), Polydefkis, Michael (author), Dyck, P. James B. (author), Brannagan III, Thomas H. (author), Conceição, Isabel (author), Benson, Merrill D. (author), Berk, John L. (author)
Formato: article
Idioma:eng
Publicado em: 2022
Assuntos:
Physical function
Polyneuropathy
Quality of life
Rare disease
Transthyretin amyloidosis
Texto completo:http://hdl.handle.net/10400.16/2665
País:Portugal
Oai:oai:repositorio.chporto.pt:10400.16/2665

Texto Completo

http://hdl.handle.net/10400.16/2665

Registos relacionados